Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Ambrx Biopharma Inc. AMAM
$11.40
+$0.11 (0.98%)
На 18:04, 12 мая 2023
Ключевые показатели
-
Marketcap
657578493.00000000
-
week52high
13.07
-
week52low
0.38
-
Revenue
7402000
-
P/E TTM
-41
-
Beta
0.00000000
-
EPS
-2.00000000
-
Last Dividend
0.00000000
-
Next Earnings Date
25 апр 2023 г. в 04:00
Описание компании
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Rupalla Katrin | A | 105000 | 105000 | 27 янв 2023 г. |
| Rupalla Katrin | A | 200000 | 200000 | 27 янв 2023 г. |
| Rupalla Katrin | A | 0 | 105000 | 27 янв 2023 г. |
| MAIER PAUL V | A | 105000 | 105000 | 27 янв 2023 г. |
| MAIER PAUL V | A | 210000 | 210000 | 27 янв 2023 г. |
| MAIER PAUL V | A | 0 | 105000 | 27 янв 2023 г. |
| Nelson Sonja | A | 425000 | 425000 | 27 янв 2023 г. |
| Nelson Sonja | A | 0 | 425000 | 27 янв 2023 г. |
| Nelson Sonja | A | 850000 | 850000 | 27 янв 2023 г. |
| Nelson Sonja | A | 2574596 | 2574596 | 27 янв 2023 г. |
Новостная лента
Penny Stocks To Buy? 3 With High Short Interest To Watch This Week
PennyStocks
10 янв 2023 г. в 13:51
Short squeeze stocks to watch. The post Penny Stocks To Buy?
How to Find and Evaluate Penny Stocks For Your Portfolio
PennyStocks
11 дек 2022 г. в 11:00
Use these tips for evaluating penny stocks to buy The post How to Find and Evaluate Penny Stocks For Your Portfolio appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is Ambrx (AMAM) Stock Up 400% Today?
InvestorPlace
09 дек 2022 г. в 13:32
In a topsy-turvy session today, investors may be intrigued by some of the biggest gainers and decliners as most stocks hold around the flat line. Among the leaders in terms of percentage gains today is biotech company Ambrx (NYSE: AMAM ), which has absolutely skyrocketed today.
Ambrx Biopharma to Host Corporate Update Conference Call
GlobeNewsWire
11 окт 2022 г. в 16:05
Conference call to discuss outcome of the strategic review that was initiated in August 2022 Conference call to discuss outcome of the strategic review that was initiated in August 2022
Ambrx Biopharma Inc. to Participate in Upcoming Investor Conferences
Business Wire
27 мая 2022 г. в 16:05
SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced that Feng Tian, Ph.D., Chairman of the Board, President and CEO of Ambrx, will participate in two upcoming investor conferences in June. Cowen's 3rd Annual Oncology Innovation Summit. Dr. Tian will participate in an analyst led fireside chat on Thursday, June 2 at 1